240 related articles for article (PubMed ID: 25327311)
1. Comparing postprandial efficacy in type 2 diabetic patients receiving mitiglinide and sitagliptin by using continuous glucose monitoring: a pilot study.
Ando K; Nishimura R; Seo C; Tsujino D; Sakamoto M; Utsunomiya K
Expert Opin Pharmacother; 2014 Dec; 15(17):2479-85. PubMed ID: 25327311
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of mitiglinide and sitagliptin, alone or in combination, on postprandial excursion and glycemic variability assessed by continuous glucose monitoring: a post hoc analysis with single-day treatment.
Baek JH; Jin SM; Kaku K; Jung JA; Kim JR; Ko JW; Kim MJ; Lee SY; Huh WS; Kim JH
Expert Opin Pharmacother; 2015 Jun; 16(8):1127-36. PubMed ID: 25881690
[TBL] [Abstract][Full Text] [Related]
3. Comparison of glycemic variability in patients with type 2 diabetes given sitagliptin or voglibose: a continuous glucose monitoring-based pilot study.
Seo C; Sakamoto M; Nishimura R; Tsujino D; Ando K; Morimoto A; Utsunomiya K
Diabetes Technol Ther; 2013 May; 15(5):378-85. PubMed ID: 23634671
[TBL] [Abstract][Full Text] [Related]
4. Effects of sitagliptin or mitiglinide as an add-on to acarbose on daily blood glucose fluctuations measured by 72 h subcutaneous continuous glucose monitoring in Japanese patients with type 2 diabetes: a prospective randomized study.
Osonoi T; Saito M; Tamasawa A; Ishida H; Osonoi Y
Expert Opin Pharmacother; 2014 Jul; 15(10):1325-35. PubMed ID: 24866329
[TBL] [Abstract][Full Text] [Related]
5. Glycemic/metabolic responses to identical meal tolerance tests at breakfast, lunch and dinner in Japanese patients with type 2 diabetes mellitus treated with a dipeptidyl peptidase-4 inhibitor and the effects of adding a mitiglinide/voglibose fixed-dose combination.
Ono Y; Kamoshima H; Nakamura A; Nomoto H
Expert Opin Pharmacother; 2014 Sep; 15(13):1785-95. PubMed ID: 25046055
[TBL] [Abstract][Full Text] [Related]
6. A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
Kishimoto M; Noda M
Cardiovasc Diabetol; 2011 Dec; 10():115. PubMed ID: 22189184
[TBL] [Abstract][Full Text] [Related]
7. Add-on treatment with mitiglinide improves residual postprandial hyperglycemia in type 2 diabetic patients receiving the combination therapy with insulin glargine and sitagliptin.
Murakami T; Nambu T; Kato T; Matsuda Y; Yonemitsu S; Muro S; Oki S
Tohoku J Exp Med; 2015 Apr; 235(4):255-60. PubMed ID: 25810423
[TBL] [Abstract][Full Text] [Related]
8. Additive postprandial glucose-lowering effects of mitiglinide and sitagliptin in patients with type 2 diabetes mellitus.
Jung JA; Kaku K; Kim JH; Kim JR; Ko JW; Lee SY; Huh W
Adv Ther; 2013 Nov; 30(11):1018-29. PubMed ID: 24249434
[TBL] [Abstract][Full Text] [Related]
9. Effects of sitagliptin on 24-h glycemic changes in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring.
Mori Y; Taniguchi Y; Matsuura K; Sezaki K; Yokoyama J; Utsunomiya K
Diabetes Technol Ther; 2011 Jul; 13(7):699-703. PubMed ID: 21504334
[TBL] [Abstract][Full Text] [Related]
10. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
Guerci B; Monnier L; Serusclat P; Petit C; Valensi P; Huet D; Raccah D; Colette C; Quéré S; Dejager S
Diabetes Metab; 2012 Oct; 38(4):359-66. PubMed ID: 22809630
[TBL] [Abstract][Full Text] [Related]
11. Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study).
Sakamoto M; Nishimura R; Irako T; Tsujino D; Ando K; Utsunomiya K
Cardiovasc Diabetol; 2012 Aug; 11():92. PubMed ID: 22867630
[TBL] [Abstract][Full Text] [Related]
12. Glucose excursions and hypoglycemia in patients with type 2 diabetes treated with mitiglinide/voglibose versus glimepiride: A randomized cross-over trial.
Fujimoto K; Shibayama Y; Yamaguchi E; Honjo S; Hamasaki A; Hamamoto Y
J Diabetes; 2018 Aug; 10(8):675-682. PubMed ID: 29493100
[TBL] [Abstract][Full Text] [Related]
13. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial.
Garg SK; Moser EG; Bode BW; Klaff LJ; Hiatt WR; Beatson C; Snell-Bergeon JK
Endocr Pract; 2013; 19(1):19-28. PubMed ID: 23186950
[TBL] [Abstract][Full Text] [Related]
14. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
Aoki K; Kamiyama H; Yoshimura K; Shibuya M; Masuda K; Terauchi Y
Acta Diabetol; 2012 Jun; 49(3):225-30. PubMed ID: 21898126
[TBL] [Abstract][Full Text] [Related]
15. Effects of add-on treatment with sitagliptin on narrowing the range of glucose fluctuations in Japanese type 2 diabetes patients receiving insulin therapy.
Mori Y; Taniguchi Y; Miyazaki S; Yokoyama J; Utsunomiya K
Diabetes Technol Ther; 2013 Mar; 15(3):237-40. PubMed ID: 23402316
[TBL] [Abstract][Full Text] [Related]
16. The glycemic/metabolic responses to meal tolerance tests at breakfast, lunch and dinner, and effects of the mitiglinide/voglibose fixed-dose combination on postprandial profiles in Japanese patients with type 2 diabetes mellitus.
Ono Y; Nakamura A; Cho KY; Nomoto H
Expert Opin Pharmacother; 2014 Feb; 15(3):311-24. PubMed ID: 24328511
[TBL] [Abstract][Full Text] [Related]
17. Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement.
Alba M; Sheng D; Guan Y; Williams-Herman D; Larson P; Sachs JR; Thornberry N; Herman G; Kaufman KD; Goldstein BJ
Curr Med Res Opin; 2009 Oct; 25(10):2507-14. PubMed ID: 19691426
[TBL] [Abstract][Full Text] [Related]
18. Mitiglinide/voglibose fixed-dose combination improves postprandial glycemic excursions in Japanese patients with type 2 diabetes mellitus.
Ono Y; Kameda H; Cho KY
Expert Opin Pharmacother; 2013 Mar; 14(4):361-70. PubMed ID: 23414242
[TBL] [Abstract][Full Text] [Related]
19. Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial.
van Genugten RE; van Raalte DH; Muskiet MH; Heymans MW; Pouwels PJ; Ouwens DM; Mari A; Diamant M
Eur J Endocrinol; 2014 Mar; 170(3):429-39. PubMed ID: 24297090
[TBL] [Abstract][Full Text] [Related]
20. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.
Xu L; Man CD; Charbonnel B; Meninger G; Davies MJ; Williams-Herman D; Cobelli C; Stein PP
Diabetes Obes Metab; 2008 Dec; 10(12):1212-20. PubMed ID: 18476982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
